The United Kingdom and the United States have hammered out a key bilateral deal that will keep zero import taxes on UK drug products entering the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to boost expenditure on drugs through the public health system. This pledge secures that import taxes on these crucial exports will remain at nothing for a duration of the next three years.
This development is in response to previous statements to dramatically increase import taxes on patented drug products, with figures mentioned up to one hundred percent.
"This arrangement between the UK bolsters the worldwide climate for cutting-edge drugs and brings much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement noted.
Commercial Impact
Pharmaceuticals represent one of the the United Kingdom's biggest goods shipped to the America, which is easily the largest buyer for major UK drugmakers.
Statistics indicate that in the one-year period leading up to the third quarter, the UK exported medicines worth over eleven billion pounds to the US. This amount made up a significant portion of total UK exports in that span.
"This deal secures work, stimulates capital expenditure and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary stated.
Specific UK Commitments
The deal involves several specific changes from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments topped 20%.
Industry Background
This agreement follows a long-running row between the pharmaceutical industry and the UK government over medicine costs and approval rates.
These tensions were heightened by arguments that American customers were paying a premium for the equivalent treatments than consumers in the other developed nations.
In recent months, several major drug company projects in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
